Rua Bioscience (NZSE:RUA) Debt-to-EBITDA : -0.03 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Rua Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$0.04 Mil. Rua Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$0.12 Mil. Rua Bioscience's annualized EBITDA for the quarter that ended in Dec. 2023 was NZ$-4.89 Mil. Rua Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Rua Bioscience's Debt-to-EBITDA or its related term are showing as below:

NZSE:RUA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.23 Med: -0.12 Max: -0.01
Current: -0.01

During the past 3 years, the highest Debt-to-EBITDA Ratio of Rua Bioscience was -0.01. The lowest was -0.23. And the median was -0.12.

NZSE:RUA's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.675 vs NZSE:RUA: -0.01

Rua Bioscience Debt-to-EBITDA Historical Data

The historical data trend for Rua Bioscience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience Debt-to-EBITDA Chart

Rua Bioscience Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-EBITDA

-0.23

-0.12

-0.01

Rua Bioscience Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.12	-0.11	-0.03	-0.01	-0.03

Competitive Comparison of Rua Bioscience's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rua Bioscience's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rua Bioscience's Debt-to-EBITDA falls into.

Rua Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Rua Bioscience's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.047	+	0.068)	/	-12.316
	=	-0.01

Rua Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.044	+	0.124)	/	-4.89
	=	-0.03

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Rua Bioscience (NZSE:RUA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Rua Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Rua Bioscience (NZSE:RUA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Commerce Place, Awapuni, Gisborne, NZL, 4071

Website

https://www.ruabio.com

Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Germany and New Zealand.

Rua Bioscience (NZSE:RUA) Headlines

No Headlines